Evidence map›Paper›PMID 34558643›Full record

ArticleInternational journal of oncology2021

lncRNA cytoskeleton regulator reduces non‑small cell lung cancer radiosensitivity by downregulating miRNA‑206 and activating prothymosin α.

Guoxiang Jiang, Honge Yu, Zhengliang Li, Fang Zhang

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed
1.9field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 29 citations in OpenAlex.

  1. Review
  2. lncRNAlyzr: Enrichment Analysis for lncRNA Sets.Journal of molecular biology · 2025
    Article
  3. Article
  4. Article
  5. Review
  6. Review
  7. Review
  8. Review
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Review
  16. Article
  17. Article
  18. Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Guoxiang JiangDepartment of Oncology Radiotherapy, Yantaishan Hospital, Yantai, Shandong 264000, P.R. China.
Honge YuDepartment of Oncology, People's Hospital of Haiyang, Haiyang, Shandong 265100, P.R. China.
Zhengliang LiDepartment of Oncology Radiotherapy, Yantaishan Hospital, Yantai, Shandong 264000, P.R. China.
Fang ZhangDepartment of Oncology Radiotherapy, Yantai Affiliated Hospital of Binzhou Medical University, Yantai, Shandong 264100, P.R. China.
Yantaishan Hospital · CNBinzhou Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The present study aimed to explore the role of the long noncoding RNA cytoskeleton regulator (CYTOR) in non‑small cell lung cancer (NSCLC) radiosensitivity by manipulating the microRNA (miR)‑206/prothymosin α (PTMA) axis. First, 58 pairs of NSCLC and paracancerous tissues, normal human lung epithelial cells and NSCLC cells were collected to analyze CYTOR expression and the relationship between CYTOR and NSCLC prognosis. Subsequently, CYTOR expression in radioresistant cells was assessed. Radioresistant cells with low CYTOR expression and parental cells with high CYTOR expression were established. Functional assays were then performed to assess changes in cell radiosensitivity after irradiation treatment. Subsequently, the downstream mechanism of CYTOR was explored. The binding interactions between CYTOR and miR‑206 and between miR‑206 and PTMA were predicted and certified. Xenograft transplantation was applied to confirm the role of CYTOR in the radiosensitivity of NSCLC. CYTOR was overexpressed in NSCLC and was associated with poor prognosis. CYTOR was further upregulated in NSCLC cells with radioresistance. CYTOR knockdown enhanced the radiosensitivity of NSCLC cells, while overexpression of CYTOR led to the opposite result. Mechanistically, CYTOR specifically bound to miR‑206 and silencing CYTOR promoted miR‑206 to enhance the radiosensitivity of NSCLC cells. PTMA is a target of miR‑206 and silencing CYTOR inhibited PTMA expression via miR‑206, thus promoting radiosensitivity of NSCLC cells. CYTOR knockdown also enhanced NSCLC cell radiosensitivity

Indexed as

Radiation ToleranceAnimalsCarcinoma, Non-Small-Cell LungCell Line, TumorCytoskeletonDown-RegulationHumansLung NeoplasmsMiceMice, Inbred BALB CMicroRNAsPrognosisProtein PrecursorsRNA, Long NoncodingThymosinMicroRNAsMIRN206 microRNA, humanProtein Precursorsprothymosin alphaRNA, Long NoncodingThymosincompeting endogenous RNAlong noncoding RNA cytoskeleton regulatormiRNA‑206non‑small cell lung cancerPTMAradiotherapysubcellular localization

Identifiers

PMID34558643
PMCPMC8480387
OpenAlexW3201069161

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.